Sizzle you are correct imho...matter of time now with Dr C. Ichim...See below...
Dr. Christine Ichim, PhD., has been Director of Research at Entest Biomedical, Inc. since July 2014. Dr. Ichim has 20 years of experience in immunology and cancer biology. She has numerous peer reviewed articles including: The orphan nuclear receptor Ear-2 (Nr2f6) is a novel negative regulator of T cell development; Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy; Kinase-independent mechanisms of resistance of leukemia stem ... cells to tyrosine kinase inhibitors; Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy and First among equals: the cancer cell hierarchy. Dr. Ichim obtained a PhD from the University of Toronto, in the Department of Medical Biophysics. She completed a Master of Science under the tutelage of Dr. Norman Iscove, where she studied the molecular biology of the leukemia stem cell. She completed a PhD focused on a novel oncogene that she identified to control leukemia stem cells. Dr. Ichim completed postdoctoral training at the Salk Institute for Biological Studies, where she conducted research on DNA biology relevant to cell division.
